CEBPB is currently being considered as an interesting drug target in AML, and molecules like sesquiterpene lactones (STLs) [44] and helenalin acetate (HA) [47] have shown promising results in disrupting the pro-oncogenic activity of the CEBPB/MYB/p300 complex by targeting directly CEBPB. Here, EP300 is linked to acute myeloid leukemia.